Search Result

Results for "

ERBB inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (67) Akt (8) Amino Acid Derivatives (1) Apoptosis (16) Autophagy (16) Btk (2) c-Met/HGFR (6) CDK (2) ERK (2) Ferroptosis (10) HSP (2) IKK (1) Isotope-Labeled Compounds (6) Itk (1) JAK (1) Orthopoxvirus (2) p38 MAPK (5) Paraptosis (1) PARP (1) PI4K (1) PROTACs (1) Raf (1) Ras (1) Src (1) Survivin (1) Trk Receptor (1)
By Research Areas:	Cancer (66) Endocrinology (1) Infection (4) Inflammation/Immunology (2) Neurological Disease (1)
Oligonucleotides:	Aptamers (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: EGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103440

*EGFR/ErbB-2/ErbB-4 inhibitor-3*	EGFR	Cancer
EGFR/ErbB-2/ErbB-4 inhibitor-3 (compound 29) is a potent tyrosine kinase inhibitor with IC₅₀s of 0.3, 1.1, 0.5, 2.5, 24 nM for erbB1, erbB2, erbB4, EGF, HER, respectively . EGFR/ErbB-2/ErbB-4 inhibitor-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-112420

*EGFR/ErbB-2/ErbB-4 inhibitor-2*	EGFR	Cancer
EGFR/ErbB-2/ErbB-4 inhibitor-2 (Compound 5) is a EGFR and *ErbB* inhibitor with IC₅₀s of 0.017 μM, 0.08 μM, 1.91 μM .

HY-50898

Lapatinib Maximum Cited Publications 70 Publications Verification GW572016; GW2016	EGFR Autophagy Ferroptosis	Cancer
Lapatinib (GW572016) is a potent inhibitor of the *ErbB-2* and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and *ErbB-2* of 10.2 and 9.8 nM, respectively .

HY-50898A

Lapatinib ditosylate Maximum Cited Publications 70 Publications Verification GW572016 ditosylate; GW2016 ditosylate	EGFR Autophagy Ferroptosis	Cancer
Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the *ErbB-2* and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and *ErbB-2* of 10.2 and 9.8 nM, respectively .

HY-50898B

Lapatinib ditosylate monohydrate Maximum Cited Publications 70 Publications Verification GW572016 ditosylate monohydrate; GW2016 ditosylate monohydrate	EGFR Autophagy Ferroptosis	Cancer
Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the *ErbB-2* and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and *ErbB-2* of 10.2 and 9.8 nM, respectively .

HY-156639

*EGFR/ErbB-2 inhibitor-1*	EGFR	Cancer
EGFR/ErbB-2 inhibitor-1 is a ErbB2/HER2 inhibitor .

HY-110039

BIBX 1382 dihydrochloride	EGFR	Infection
BIBX 1382 dihydrochloride is an ErbB kinase inhibitor with significant antiviral activity. BIBX 1382 affects the ability of viruses to enter host cells by inhibiting members of the ErbB kinase family. It can be used to study the interaction mechanism between virus and host and the broad spectrum intervention of highly pathogenic viruses .

HY-153856A

TAS2940 fumarate	EGFR	Cancer
TAS2940 fumarate is a brain-penetrable, orally active, irreversible and selective *pan-ERBB* inhibitor. TAS2940 fumarate against wild-type HER2, HER2 V777L, and A775_G776insYVMA with IC₅₀ values of 5.6 nM, 2.1 nM, and 1.0 nM, respectively. TAS2940 fumarate can be used for the study of tumors with HER2 and EGFR aberrations .

HY-153856

TAS2940	EGFR	Cancer
TAS2940 is a brain-penetrable, orally active, irreversible and selective *pan-ERBB* inhibitor. TAS2940 against wild-type HER2, HER2 V777L, and A775_G776insYVMA with IC₅₀ values of 5.6 nM, 2.1 nM, and 1.0 nM, respectively. TAS2940 can be used for the study of tumors with HER2 and EGFR aberrations .

HY-137028

2′-Thioadenosine PD157432	EGFR	Cancer
2'-Thioadenosine (PD157432) is a selective and irreversible inhibitor of *ErbB-1* and *ErbB-2, with an IC₅₀* of 45 µM for ErbB-2. 2'-Thioadenosine covalently inactivates ErbB-1 via modification of a cysteine residue at the active site .

HY-50898C

Lapatinib tosylate GW572016 tosylate; GW2016 tosylate	EGFR Ferroptosis Autophagy	Cancer
Lapatinib (GW572016) tosylate is a potent, orally active inhibitor of the *ErbB-2* and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and *ErbB-2* of 10.2 and 9.8 nM, respectively .

HY-103441

JNJ28871063 hydrochloride	EGFR	Cancer
JNJ28871063 hydrochloride is an orally active, highly selective and ATP competitive *pan-ErbB* kinase** inhibitor with IC₅₀ values of 22 nM, 38 nM, and 21 nM for ErbB1, ErbB2, and ErbB4, respectively. JNJ28871063 hydrochloride inhibits phosphorylation of functionally important tyrosine residues in both EGFR and ErbB2. JNJ28871063 hydrochloride crosses the blood-brain barrier and has antitumor activity in human tumor xenograft models that overexpress EGFR and ErbB2 .

HY-18609

PD158780 2 Publications Verification	EGFR	Cancer
PD158780 is a potent EGFR family inhibitor with IC₅₀s of 8 pM, 49, 52, 52 nM for EGFR, ErbB2, ErbB3, and ErbB4, respectively.

HY-50898S1

Lapatinib-d7 dihydrochloride GW572016-dd₇ dihydrochloride; GW2016-dd₇ dihydrochloride	Isotope-Labeled Compounds EGFR Autophagy Ferroptosis	Cancer
Lapatinib-d₇ (dihydrochloride) is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

HY-50898S2

Lapatinib-d5 GW572016-d₅; GW2016-d₅	Isotope-Labeled Compounds EGFR Autophagy Ferroptosis	Cancer
Lapatinib-d₅ is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

HY-50898S3

Lapatinib-d4-1 GW572016-d₄-1; GW2016-d₄-1	Isotope-Labeled Compounds EGFR Autophagy Ferroptosis	Cancer
Lapatinib-d₄-1 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

HY-13272

Dacomitinib 20+ Cited Publications PF-00299804; PF-299804	EGFR Apoptosis	Cancer
Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the *ERBB* family of kinases with IC₅₀s of 6 nM, 45.7 nM and 73.7 nM for EGFR, *ERBB2, and ERBB4*, respectively .

HY-50898S

Lapatinib-d4 GW572016-d₄; GW2016-d₄	EGFR Autophagy Ferroptosis	Cancer
Lapatinib-d₄ is the deuterium labeled Lapatinib (HY-50898). Lapatinib is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1][2].

HY-50898R

Lapatinib (Standard)	EGFR Autophagy Ferroptosis	Cancer
Lapatinib (Standard) is the analytical standard of Lapatinib. This product is intended for research and analytical applications. Lapatinib (GW572016) is a potent inhibitor of the *ErbB-2* and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and *ErbB-2* of 10.2 and 9.8 nM, respectively .

HY-W006886

Fmoc-(R)-2-(7-octenyl)Ala-OH	Amino Acid Derivatives	Others
Fmoc-(R)-2-(7-octenyl)Ala-OH is an amino acid derivative with an Fmoc protecting group that can be used to synthesize inhibitor peptides that combinatorially inactivate ErbB1, ErbB2, and ErbB3 .

HY-50898CS

Lapatinib-d4 tosylate GW572016-d₄ tosylate; GW2016-d₄ tosylate	Isotope-Labeled Compounds EGFR Autophagy Ferroptosis	Cancer
Lapatinib-d₄ (GW572016-d₄) tosylate is deuterium labeled Lapatinib (tosylate). Lapatinib (GW572016) tosylate is a potent, orally active inhibitor of the *ErbB-2* and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and *ErbB-2* of 10.2 and 9.8 nM, respectively .

HY-13050A

Sapitinib fumarate AZD-8931 fumarate	EGFR	Cancer
Sapitinib fumarate is a reversible, ATP competitive EGFR inhibitor of with IC₅₀s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.

HY-13272S2

Dacomitinib-d10 dihydrochloride PF-00299804-d₁₀ dihydrochloride; PF-299804-d₁₀ dihydrochloride	Isotope-Labeled Compounds EGFR Apoptosis	Cancer
Dacomitinib-d₁₀ (dihydrochloride) is the deuterium labeled Dacomitinib dihydrochloride. Dacomitinib (PF-00299804) dihydrochloride is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively[1].

HY-13272S3

Dacomitinib-d10 PF-00299804-d₁₀; PF-299804-d₁₀	Isotope-Labeled Compounds EGFR Apoptosis	Cancer
Dacomitinib-d₁₀ is deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively[1].

HY-14347

EBE-A22	Others	Cancer
EBE-A22 is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.

HY-13272R

Dacomitinib (Standard)	EGFR Apoptosis	Cancer
Dacomitinib (Standard) is the analytical standard of Dacomitinib. This product is intended for research and analytical applications. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the *ERBB* family of kinases with IC₅₀s of 6 nM, 45.7 nM and 73.7 nM for EGFR, *ERBB2, and ERBB4*, respectively .

HY-13050

Sapitinib 5+ Cited Publications AZD-8931	EGFR	Cancer
Sapitinib (AZD-8931) is a reversible, ATP competitive EGFR inhibitor of with IC₅₀s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.

HY-129288

GW837016X NEU-391	EGFR Paraptosis	Infection
GW837016X (NEU-391) is an orally active *ErbB-2* kinase covalent inhibitor. GW837016X also is a potent antitrypanosome agent. GW837016X inhibits mitosis and cytokinesis .

HY-118532

Tyrphostin AG30 1 Publications Verification AG30	EGFR	Cancer
Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts .

HY-160068

2-2(t) aptamer sodium	EGFR	Cancer
2-2(t) aptamer sodium is a 42-nucleotide trimeric complex of aptamer (2-2) targeting *ErbB-2. 2-2(t) aptamer sodium inhibits* the growth of gastric cancer cells in vitro and in vivo .

HY-15375

Allitinib 1 Publications Verification AST-1306; ALS 1306	EGFR	Cancer
Allitinib (AST-1306) is an orally active and irreversible EGFR and *ErbB2* inhibitor with IC₅₀s of 0.5 and 3 nM, respectively. Allitinib also inhibits *ErbB4* with an IC₅₀ of 0.8 nM. Allitinib is an anilino-quinazoline compound and has anti-cancer activity .

HY-10045

AEE788 3 Publications Verification NVP-AEE 788	EGFR Apoptosis	Cancer
AEE788 is an inhibitor of the EGFR and *ErbB2* with IC₅₀ values of 2 and 6 nM, respectively.

HY-13427

Allitinib tosylate 1 Publications Verification AST-1306 (TsOH)	EGFR	Cancer
Allitinib tosylate (AST-1306 (TsOH)) is an orally active and irreversible EGFR and *ErbB2* inhibitor with IC₅₀s of 0.5 and 3 nM, respectively. Allitinib tosylate also inhibits *ErbB4* with an IC₅₀ of 0.8 nM. Allitinib tosylate is an anilino-quinazoline compound and has anti-cancer activity

HY-164548

WK88-1	HSP Apoptosis	Cancer
WK88-1, a Hsp90 inhibitor, induces overall degradation of multiple oncogenic signaling molecules including EGFR, ErbB2 and ErbB3, leading to subsequent growth arrest and apoptosis in the Gefitinib-resistant H1975 cell line .

HY-14674

CP-724714 4 Publications Verification	EGFR Apoptosis	Cancer
CP-724714 is a potent, selective and orally active ErbB2 (HER2) tyrosine kinase inhibitor, with an IC₅₀ of 10 nM. CP-724714 displays a marked selectivity against EGFR kinase (IC₅₀=6400 nM). CP-724714 potently inhibits ErbB2 receptor autophosphorylation in intact cells. Antitumor activities .

HY-20878

Tyrphostin AG 879 2 Publications Verification AG 879	Trk Receptor EGFR Apoptosis	Cancer
Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits TrKA phosphorylation (IC₅₀ of 10 μM), but not TrKB and TrKC. Tyrphostin AG 879 is also a selective *ErbB2* tyrosine kinase inhibitor with an IC₅₀ of 1 μM, and has at least 500-fold higher selectivity to *ErbB2* than EGFR. Tyrphostin AG 879 has anticancer activity .

HY-100499

Tyrphostin AG 528 1 Publications Verification Tyrphostin B66; AG 528	EGFR	Cancer
Tyrphostin AG 528 is an inhibitor of EGFR and *ErbB2* with IC₅₀s of 4.9 and 2.1 μM, respectively. Tyrphostin AG 528 (Tyrphostin B66) is a protein tyrosine kinase inhibitor, with IC₅₀s of 4.9 μM for epidermal growth factor receptors (EGFR) and 2.1 μM for *ErbB2* . Tyrphostin AG 528 is also an anticancer agent .

HY-143874

HER2-IN-7	EGFR	Cancer
HER2-IN-7 is a potent inhibitor of HER2. Deregulation of ErbB family signalling modulates proliferation, invasion, metastasis, angiogenesis, and tumour cell survival. HER2-IN-7 has the potential for the research of diseases associated ErbBs (especially HER2), including cancer (extracted from patent WO2019214634A1, compound 23) .

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to *ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits* the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-116437

Selatinib	EGFR	Cancer
Selatinib is a reversible and orally active dual EGFR and *ErbB2* inhibitor with IC₅₀s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects .

HY-118263

Dacomitinib hydrate 20+ Cited Publications PF-00299804 hydrate; PF-299804 hydrate	EGFR	Cancer
Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC) .

HY-32718

Pelitinib 5 Publications Verification EKB-569; WAY-EKB 569	EGFR Src	Cancer
Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of EGFR with an IC₅₀ of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC₅₀s of 282, 800, and 1255 nM, respectively.

HY-10531

ARRY-380 analog	EGFR	Cancer
ARRY-380 analog, an inhibitor of EGFR (ErbB1), is extracted from patent WO2015153959A2, compound 249 . ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2 .

HY-103443

HKI-357	EGFR	Cancer
HKI-357 is an irreversible dual inhibitor of EGFR and *ERBB2* with IC₅₀s of 34 nM and 33 nM, respectively. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation .

HY-10367A

Canertinib dihydrochloride 5+ Cited Publications CI-1033 dihydrochloride; PD-183805 dihydrochloride	EGFR Orthopoxvirus	Infection Cancer
Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and *ErbB2* autophosphorylation with IC₅₀s of 7.4 and 9 nM. Canertinib dihydrochloride is active against vaccinia virus respiratory infection in mice .

HY-W008914

(E/Z)-CP-724714	EGFR	Cancer
(E/Z)-CP-724714 is a racemic compound of (E)-CP-724714 and (Z)-CP-724714 isomers. CP-724714 is a potent and selective orally active ErbB2 (HER2) inhibitor .

HY-103443A

HKI-357 dimaleate	EGFR	Cancer
HKI-357 dimaleate is an irreversible dual inhibitor of EGFR and *ERBB2* with IC₅₀s of 34 nM and 33 nM, respectively. HKI-357 dimaleate suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation .

HY-10367

Canertinib 5+ Cited Publications CI-1033; PD-183805	EGFR Orthopoxvirus	Infection Cancer
Canertinib (CI-1033;PD-183805) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and *ErbB2* autophosphorylation with IC₅₀s of 7.4 and 9 nM. Canertinib is active against vaccinia virus respiratory infection in mice .

HY-13896

PD168393 2 Publications Verification	EGFR Autophagy Apoptosis	Cancer
PD168393?is a potent, selective and cell-permeable inhibitor of EGFR tyrosine kinase and *ErbB2. PD168393 irreversiblely inactivates EGF receptor ( IC₅₀*=0.7 nM) and is inactive against insulin receptor, PDGFR, FGFR and PKC .

HY-103439

GW583340 dihydrochloride	EGFR	Cancer
GW 583340 dihydrochloride is a potent dual *EGFR/ErbB2* tyrosine kinase inhibitor (IC₅₀: 0.01 and 0.014 μM respectively). GW 583340 dihydrochloride reverses ABCG2- and ABCB1-mediated drug resistance. GW 583340 dihydrochloride has anti-cancer activity .

Cat. No.	Product Name	Target	Research Area

HY-W006886

Fmoc-(R)-2-(7-octenyl)Ala-OH	Amino Acid Derivatives	Others
Fmoc-(R)-2-(7-octenyl)Ala-OH is an amino acid derivative with an Fmoc protecting group that can be used to synthesize inhibitor peptides that combinatorially inactivate ErbB1, ErbB2, and ErbB3 .

Cat. No.	Product Name	Target	Research Area

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to *ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits* the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P99268

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ERBB 3 Recombinant Antibody	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

Cat. No.	Product Name	Chemical Structure

HY-50898S

Lapatinib-d4
Lapatinib-d₄ is the deuterium labeled Lapatinib (HY-50898). Lapatinib is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1][2].

HY-50898S1

Lapatinib-d7 dihydrochloride
Lapatinib-d₇ (dihydrochloride) is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

HY-50898S2

Lapatinib-d5
Lapatinib-d₅ is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

HY-50898S3

Lapatinib-d4-1
Lapatinib-d₄-1 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

HY-50898CS

Lapatinib-d4 tosylate
Lapatinib-d₄ (GW572016-d₄) tosylate is deuterium labeled Lapatinib (tosylate). Lapatinib (GW572016) tosylate is a potent, orally active inhibitor of the *ErbB-2* and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and *ErbB-2* of 10.2 and 9.8 nM, respectively .

HY-13272S2

Dacomitinib-d10 dihydrochloride
Dacomitinib-d₁₀ (dihydrochloride) is the deuterium labeled Dacomitinib dihydrochloride. Dacomitinib (PF-00299804) dihydrochloride is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively[1].

HY-13272S3

Dacomitinib-d10
Dacomitinib-d₁₀ is deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively[1].

HY-B0793S1

AZ-5104-d2
AZ-5104-d₂ is the deuterium labeled AZ-5104. AZ-5104 is an EGFR inhibitor with IC50s of 1 nM, 6 nM, 1 nM, 25 nM and 7 nM for EGFRL858R/T790M, EGFRL858R, EGFRL861Q, EGFR and ErbB4, respectively[1].

Cat. No.	Product Name		Classification

HY-160068

2-2(t) aptamer sodium		Aptamers
2-2(t) aptamer sodium is a 42-nucleotide trimeric complex of aptamer (2-2) targeting *ErbB-2. 2-2(t) aptamer sodium inhibits* the growth of gastric cancer cells in vitro and in vivo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: